← Otros eventos

ZeCardio: a versatile platform for cardiovascular drug and target discovery

Ponencia impartida por Javier Terriente, PhD. Chief Scientific Officer, Zeclinics

El 28 de noviembre, a las 11.30 horas, en la sala 0.22 (aula docente), tendrá lugar la conferencia ZeCardio: a versatile platform for cardiovascular drug and target discovery, a cargo de Javier Terriente, PhD. Chief Scientific Officer, Zeclinics, Barcelona.

Javier is Chief Scientific Officer (CSO) and co-founder at ZeClinics from 2013. As ZeClinics CSO, he is in charge of supervising every scientific aspect of ZeClinics activity: bringing new ideas, developing new products, assessing the quality of services and drug discovery platforms, asking for public and private funding, coordinating research projects, helping the commercial area in designing scientific proposals and searching for new clients and managing a growing and talented scientific team. Before founding Zeclinics, Javier was an academic researcher in the field of developmental neurobiology. He did his PhD in the CBM-SO at Madrid (Spain) followed by two postdoctoral stays at NIMR-MRC in London (UK) and at DCEXS/UPF in Barcelona (Spain). In overall, he has 15 years of experience across different academic institutions and 5 years in the pharmaceutical industry.

ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for: 1) performing target validation, 2) developing disease models for several indications and 3) addressing the safety and efficacy of novel chemical molecules. ZeClinics' business strength relies on high scientific expertise and top-notch research facilities, combined with strategic industrial partnerships and academic collaborations. The aim of the company is to challenge the traditional drug discovery pipeline by offering an economic, fast and robust array of customized assays, designed to address the safety and biomedical relevance of novel molecules. Another strength is the use of genome editing technologies, such as CRISPR, for performing target validation and developing innovative disease model. In addition to the CRO activity, Zeclinics is developing different drug discovery pipelines in the cardiovascular field.